Presymptomatic cerebral blood flow changes in CHMP2B mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRI by Lunau, Line et al.
Presymptomatic cerebral blood ﬂow
changes in CHMP2B mutation carriers of
familial frontotemporal dementia
(FTD-3), measured with MRI
Line Lunau,
1 Kim Mouridsen,
1 Anders Rodell,
1 Leif Østergaard,
1
Jørgen Erik Nielsen,
2,3 Adrian Isaacs,
4 Peter Johannsen,
2 The FReJA Consortium
ABSTRACT
Objectives: To assess functional changes measured by
cerebral blood ﬂow (CBF) in the presymptomatic stage
of frontotemporal dementia linked to chromosome 3
(FTD-3) caused by a truncating mutation in CHMP2B.
Design: Caseecontrol study.
Setting: A memory clinic and tertiary referrals centre
for dementia and inherited neurodegenerative
disorders.
Participants: The authors included 11
presymptomatic CHMP2B mutation carriers and seven
ﬁrst-degree-related family non-carriers. Participants
were MRI scanned twice with an interval of 15 months.
Primary and secondary outcome measures: Local
functional changes in brain tissue perfusion were
measured as CBF with two different MR techniques,
gradient echo (GRE) and spin echo (SE), focusing on
CBF in all cerebral vessels (GRE) and cerebral
capillaries (SE), respectively. As planned, data analysis
included co-registration of perfusion images to
structural T1 images. Perfusion data were then
extracted from seven regions-of-interest, normalised
to white matter and statistically compared between
carriers and non-carriers.
Results: For SE, contrasts between carriers and non-
carriers showed signiﬁcant differences in temporal,
occipital and parietal lobes and in hippocampus. There
was no evidence of changes from baseline to follow-
up. For GRE, there were no signiﬁcant differences
between carriers and non-carriers.
Conclusions: Signiﬁcantly decreased CBF was found
in presymptomatic CHMP2B mutation carriers in
occipital-and parietal lobes. Comparing SE with GRE,
data indicate that FTD-3 vascular pathology might
primarily affect brain capillaries.
INTRODUCTION
Frontotemporal dementia linked to chro-
mosome 3 (FTD-3) is an autosomal dominant
inherited neurodegenerative disease ﬁrst
described in a large Danish family. In 2005,
a truncating mutation in the CHMP2B gene
on chromosome 3 was identiﬁed,
1 affecting
one of the proteins in the endosomal
ESCRTIII complex leading to disruption of
the endosomal transport and degradation of
proteins.
1e4 A second, distinct, truncating
CHMP2B mutation was subsequently identi-
ﬁed in a familial Belgian frontotemporal
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ARTICLE SUMMARY
Article focus
- Frontotemporal dementia linked to chromosome
3 (FTD-3) is an autosomal dominantly inherited
neurodegenerative disease caused byatruncating
mutation in CHMP2B.
- The study assesses change in CBF in the
presymptomatic stage of CHMP2B mutation
carriers compared with ﬁrst-degree-related non-
carriers.
- CBF was measured with GRE MR techniques
focusing on CBF in all cerebral vessels and with
SE technique focusing on cerebral capillaries.
Key messages
- Eleven presymptomatic mutation carriers were
compared with seven ﬁrst-degree-related family
non-carriers and scanned twice with 15 months
in between.
- For capillary measurements (SE), contrasts
between carriers and non-carriers showed signif-
icant differences in temporal, occipital and
parietal lobes and in the hippocampus. There
was no difference for the measurements over all
vessels (GRE) and no difference over time.
- Comparison of SE with GRE, data indicate that
FTD-3 vascular pathology primarily affect brain
capillaries.
Strength and limitations of this study
- Limitations of the study are the relative few
participants and the short follow-up time
compared with the disease duration.
- The strength is that all 11 patients carry the exact
same mutation and that the non-mutation
carriers all are ﬁrst-degree relatives, thus
reducing the genetic variability.
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5 The clinical symptoms of the disease
begin with subtle personality changes. Patients become
disinhibited with lack of empathy and inappropriate
emotional responses. Some develop hyperorality with,
for instance, chain smoking. Other cortical cognitive
deﬁcits like dyscalculia have been seen as an early
symptom. Neuropsychological testing most often
demonstrate that also posteriorly located cognitive
functions like visuospatial function are affected. The
patients often have little to no insight. In the initial
phase cranial nerves, pyramidal and extrapyramidal
functions are in most instances normal, although some
patients have developed features of motor neuron
involvement. The average age of onset is 57 years with
a very wide range from 46 to 67 years of age, although
exact age of onset is difﬁcult to determine in the indi-
vidual case, as the onset in many cases are subtle and
slowly progressive behavioural changes.
The disease is steadily progressive. In later stages, the
patients are often either predominantly apathetic or
exhibit more aggressive behaviour. Some patients
develop parkinsonian features, dystonia, pyramidal signs
or myoclonia. In terminal stages, the patients are
bedridden. The average duration of disease is approxi-
mately 8 years with a large variation.
6
Structural neuroimaging with CT and MRI show
generalised cortical and central atrophy and often
widening of the posterior lateral ventricles. No white
matter changes are seen. In presymptomatic carriers,
localised cortical
7 and more generalised atrophy
8 has
been demonstrated.
H2
15Oepositron emission tomography (PET) scan-
ning of regional cerebral blood ﬂow (rCBF) in symp-
tomatic individuals showed severe and widespread rCBF
deﬁcits, most prominent in frontal, parietal and
temporal lobes and normal rCBF only in primary visual
cortex, thalami and basal ganglia.
6
FTD-3 is characterised pathologically by the presence
of ubiquitin and p62 inclusions that are negative for
both TDP-43 and FUS.
9e11
Cerebral blood ﬂow (CBF) and perfusion measured by
MRI can be performed by two different types of perfu-
sion-weighted imaging: gradient echo (GRE) and spin
echo (SE). GRE is equally sensitive to signals in all vessel
sizes, whereas the SE sequence reﬂects signals mainly
from the capillary bed, as signals from larger vessels are
effectively refocused in SE.
12 13 The MRI method has
been validated against PET CBF measurements in
Alzheimer’s disease showing a very good correlations
between the two methods.
14 15
The purpose of this study was to assess changes in
rCBF measured with MRI in the presymptomatic stage of
subjects with CHMP2B mutation compared with ﬁrst-
degree relatives without the mutation.
Based on previous PET measurements of rCBF in
symptomatic FTD-3 cases, we hypothesised that a trunca-
tion mutation in CHMP2B leads to preclinical functional
changes in the CBF.
METHODS
The study fulﬁls the Helsinki II declaration and was
approved by the regional research ethics committee.
Subjects were recruited through a family contact group.
All participants gave written informed consent prior to
participation.
Subjects
Eighteen ﬁrst-degree-related family members without
clinical disease were recruited from the Danish FTD-3
family. All subjects were anonymously tested for the
CHMP2B mutation, as some subjects did not want to
know their genetic status. Neither the subjects nor any
member of the research group, who has contact with the
subjects have been informed of the genetic status of
individual participants. Genetic testing was performed at
the Institute of Neurology, London, UK (AI), and at the
Section of Neurogenetics, Copenhagen, Denmark
(JEN), and resulted in 11 being carriers and seven non-
carriers.
Clinical interview and neurological examination was
carried out by an experienced neurologist specialised in
dementia and FTD (PJ), and for each subject, a close
relative, usually the spouse, was interviewed in a semi-
structured manner. None of the participants fulﬁlled
criteria for FTD, and the interviews and testing did not
indicate symptomatic onset of clinical FTD-3 disease.
There was no change in reported health, behaviour or
clinical status between the ﬁrst and the second assess-
ment. Hence, all participants were presymptomatic all
through the study period. They were either working full
time or retired due to age.
Image acquisition
All individuals were scanned twice on a 3T Signa Excite
MRI-scanner, a baseline and a follow-up scan. The
average scan interval time was 15 months.
T1 axial images were acquired with (TE/TR¼2.89/
6.396). Standard dynamic susceptibility contrast MRI was
performed with GRE (TE/TR¼30/1500) and SE (TE/
TR¼60/1500) following intravenously administered
contrast agent (gadobutrol) 10 ml/kg and 5 ml/kg,
respectively, for GRE and SE. Injection rate was 5 ml/s,
followed by infusion of 30 ml saline with the same
injection rate. In plane, resolution was 1283128.
Image analysis
Structural T2-weighted and perfusion images were line-
arly co-registered to structural T1-weighted images using
a six-parameter rigid-body transformation (three trans-
lation, three rotation, scale¼1.0) and a mutual infor-
mation similarity measure.
16 17 Representative images of
transaxial maps of capillary rCBF from the SE sequence
are shown in ﬁgure 1.
The T1 images for all subjects were iteratively regis-
tered to a common mean of the population using the
Montreal Neurological Institute (MNI) ICBM 152_linear
average brain as initial reference space. The registration
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CBF in presymptomatic FTD-3method used was a modiﬁcation of the linear and non-
linear method for model-based segmentation.
18 Using
this approach, we achieved a population-speciﬁc average
model, which is referred to as the FTD-3 standard brain
(FTD-3 standard space).
The FTD-3 standard brain was segmented using
a model-based approach developed at MNI.
18 19 Existing
regions-of-interest (ROIs) in (MNI) ICBM 152_linear
space were ﬁrst transformed to the FTD-3 standard space
using a linear and non-linear registration but without
tissue classiﬁcation. The resulting ROIs in the FTD-3
standard space were then individualised using the
previously determined non-linear transform between
each subjects T1 native space and the FTD-3 standard
space.
The ROIs were selected based on previous PET CBF
studies in symptomatic FTD-3 cases (partly described
in
6) and included all major lobes, see table 2 and ﬁgure
1 for a complete list. As no asymmetry has been shown
neither in the pathology nor on previous structural scans
in FTD-3, the ROIs include both left- and right-hemi-
spheric regions.
On the raw perfusion images, arterial input functions
were selected semi-automatically.
20 Maps of relative CBF
and CBV were calculated on a voxel-by-voxel basis, using
singular value decomposition with a block-circulant
deconvolution matrix.
20 Mean transit time was calcu-
lated, using the central volume theorem, as the ratio
between CBV and CBF.
13
Statistics
Data analysis was carried out in the program ‘R’ (http://
www.r-project.org).
On average, there was a non-signiﬁcant tendency to
higher CBF estimates in the second scan compared with
the ﬁrst scan. Therefore, the following statistical model
was chosen to account for this. A linear model (M0) was
ﬁtted, which included the interaction between the
carrier and scan effects (from baseline to follow-up).
Another model (M1) was ﬁtted without this interaction.
To accommodate the correlation between successive
scans, both models included a random effect for
subjects. A likelihood ratio test was performed for the
reduction from M0 to M1 in order to test whether carrier
status was independent of scan time for each ROI.
Contrasts between groups and scan times, respectively,
were also estimated.
RESULTS
Demographics of the subjects are shown in table 1.
Three dropped out, thus only providing a baseline scan.
As some of the participants did not want to be informed
of the genetic carrier status, information on carrier
status at a subject level cannot be stated. Due to a tech-
nical error during one scan, one subject’s baseline SE
image was excluded.
On SE, the likelihood ratio test showed signiﬁcant
differences in rCBF between carriers and non-carriers in
four out of seven ROIs (table 2). On GRE, there were no
signiﬁcant differences between the two groups.
The likelihood ratio test showed no signiﬁcant inter-
actions between carrier and scan effects, neither for SE
Figure 1 Representative images
of transaxial maps of capillary
regional cerebral blood ﬂow (spin
echo sequence; arbitrary values
normalised to white matter) in
a presymptomatic mutation non-
carrier (A) and a mutation carrier
(B). Examples of some of the
regions-of-interest in red colour
used for the analyses (C: occipital
cortex; D: frontal cortex; E: white
matter and F: temporal cortex).
Table 1 Demographics of CHMP2B mutation carriers and
ﬁrst-degree family non-carriers
Carriers Non-carriers
N1 1 7
Women 2 2
Mean age (SD) 56 years (5.9) 55 years (6.2)
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CBF in presymptomatic FTD-3nor GRE, except for GRE for the hippocampus ROI.
This lack of interaction suggests that the differences in
rCBF between carriers and non-carriers are unchanged
from baseline to follow-up.
On boxplots (ﬁgures 2 and 3), there is a trend towards
more pronounced group differences on follow-up
compared with baseline, though this could not be
conﬁrmed through the statistical analysis. One of the
non-carriers had a signiﬁcantly lower CBF than all other
subjects in the basal ganglia but not in other regions.
There is no explanation for this result. In the non-
carriers, there was a tendency to higher estimates of CBF
in the second scan for both SE and GRE data. The
outlier among mutation carriers in ﬁgure 2 is the same
subject in all four indicated ROIs. An analysis of the data
without this subject did not change the consistency of
the results in all regions; although with the relative small
group sizes, this subject contributes signiﬁcantly to the
statistical p value.
DISCUSSION
Presymptomatic CHMP2B mutation carriers showed
signiﬁcantly lower CBF in four of the seven pre-selected
ROIs when compared with ﬁrst-degree relatives without
the mutation. The rCBF reduction was seen in SE
measurements but not in GRE measurements. As the SE
sequences are sensitive to signal from capillaries and the
GRE sequence to the whole vascular network, the results
indicate an involvement of the capillaries in the patho-
physiology of FTD-3.
In severely affected symptomatic FTD-3 cases, we have
previously, with H2
15OePET rCBF measurements, found
pronounced and widespread decreased CBF in most of
the brain sparing the visual cortex, basal ganglia and
cerebellum.
6
These data cannot distinguish between a primary
involvement of the capillaries leading to a ﬂow reduction
or whether the ﬂow reduction is primarily related to
a decrease in the metabolic activity of neurons and glia
leading to a ﬂow reduction. As the function of CHMP2B
protein and the ESCRT complex encompasses transport
and degradation of proteins, it might also be a partly
independent and parallel pathobiological process in
neurons and in the vessel walls.
Development of a mouse model would facilitate
studies of vessel involvement in both brain and other
tissues that may quantify the involvement of capillary
hypoperfusion in the disease process.
This present ﬁnding, demonstrating pathological
changes in a presymptomatic stage of a neurodegenera-
tive disease, has similarities with a study in the
prodromal pre-dementia phase of Alzheimer’s disease,
which demonstrated 10%e23% signiﬁcant decrease in
CBF in the mesiotemporal region, amygdala and ante-
rior cingulum, compared with healthy controls.
21
In the present study, we have used a contrast-enhanced
MRI technique to measure CBF. Arterial spin-labelled
MRI is a promising other type of MRI technique that can
be used for CBF measurements where an intravenous
contrast infusion is not necessary and therefore is easier
to apply and with a lower cost. The drawback is that the
arterial spin label method does not measure the micro-
vasculature and therefore with the present ﬁndings
would not have been suitable for this study.
A few other studies have assessed primarily structural
brain change in presymptomatic mutations carriers of
Table 2 Differences (contrasts) in normalised regional
cerebral blood ﬂow between CHMP2B mutation carriers
and non-carriers
Gradient echo
(all vessels)
Spin echo
(capillaries)
Frontal 0.11 0.16
Temporal 0.09 0.19*
Hippocampus  0.01 0.18*
Parietal 0.15 0.28*
Occipital 0.02 0.21*
Cerebellum  0.09 0.11
Basal ganglia 0.02 0.24
*p<0.05 on the likelihood ratio test.
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Figure 2 Boxplots showing capillary (spin echo) regional cerebral blood ﬂow differences at baseline between presymptomatic
mutation carriers and non-carriers (‘dots’ ¼ outliers). CBF, cerebral blood ﬂow.
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CBF in presymptomatic FTD-3other types of frontotemporal dementia. These studies
describe early and presymptomatic structural changes,
measured both as decreased whole-brain volume
22 23
and as reduced fractional anisotropy in white matter.
23
Thus subtle structural and functional brain changes can
be demonstrated in subjects very likely on the course to
a clinical manifestation of a neurodegenerative disease.
Further research is needed to elucidate the relation
between the altered function of the CHMP2B gene, the
affected cellular processes,
24 the global pattern of
atrophy
78and ﬁnally the changes in CBF which are
presented here.
There are limitations of this study. First, the number of
subjects is low, but although the Danish FTD-3 family is
large, not all are willing to participate and the number of
subjects in a relevant age of up to 15 years before average
onset is lower giving a natural limitation of group sizes.
A strength of this study is that the control group are
ﬁrst-degree relatives only. Thus, some variance is elimi-
nated compared with a control group of unrelated
subjects. There is also an ethical argument for using ﬁrst-
degree relatives in order to be able to keep clinicians
and the family blinded to the genetic status of the indi-
viduals as only some of the participants have chosen to
go through the clinical process of genetic counselling
and testing.
Second, a Volume-Of-Interest (VOI)-based approach
has the disadvantage of the a priori deﬁnition of VOIs
compared with a voxel-based approach. This may have
affected the ﬁndings. The voxel-based approach was
chosen after comparison of PET CBF studies in symp-
tomatic FTD-3 cases and results indicating that changes
in mutation carriers probably are more global than focal
in nature.
6 8 As discussed by Rohrer et al,
8 the patho-
physiological process in FTD-3 seems more widespread
in the cerebrum than indicate by the phenotype. The
locations of the ROIs were therefore chosen based on
the changes seen in symptomatic cases. The volume of
the ROIs chosen is relatively small, as this analysis was
speciﬁcally focused on delineating the cortex. The
reason for choosing cortical volumes was to increase the
sensitivity of picking up changes, as it is likely that the
early changes are most likely cortical. Contrarily, there
might be a problem with partial volume effects, where
brain atrophy mimics perfusion reduction as conse-
quence of the cortical atrophy, since we have already
previously shown decreased cortical thickness in this
group.
7 However, compared with SPECT and PET, the
resolution in perfusion-weighted MRI is smaller, which
decreases the partial volume effects problem. The
strength of the results is the consistent ﬁndings in all
assessed regions in the two scan series.
Very few studies have assessed changes of physiological
brain processes in a presymptomatic stage of familial
dementia. Knowledge about functional changes such as
reduced blood ﬂow in relation to capillary involvement
in presymptomatic mutation carriers will have implica-
tions for both studies of the FTD-3 animal models as well
as for the clinical studies of FTD-3 patients. Ultimately, it
may have implications for early detection and possible
future treatment regimes in FTD and other neurode-
generative disease.
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